Capmatinib suppresses LPS-induced interaction between HUVECs and THP-1 monocytes through suppression of inflammatory responses

BACKGROUND: Capmatinib (CAP) is a drug that has been used to treat non-small cell lung cancer (NSCLC) in adults. Presently, its novel effects on skeletal muscle insulin signaling, inflammation, and lipogenesis in adipocytes have been uncovered with a perspective of drug repositioning. However, the i...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Hyung Sub, Abd El-Aty, A.M., Jeong, Ji Hoon, Lee, Taeseung, Jung, Tae Woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chang Gung University 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267969/
https://www.ncbi.nlm.nih.gov/pubmed/35483573
http://dx.doi.org/10.1016/j.bj.2022.04.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267969/
https://www.ncbi.nlm.nih.gov/pubmed/35483573
http://dx.doi.org/10.1016/j.bj.2022.04.005

Ejemplares similares